DNC inhibitors, which stand for "Di-Nucleotide Cyclase inhibitors," represent a chemically diverse and intriguing class of compounds that exert their effects at the molecular crossroads of cellular signaling. These compounds are integral to the fine-tuned regulation of biological responses, acting as modulators of enzymes known as di-nucleotide cyclases. These enzymes are central to the synthesis and degradation of cyclic di-nucleotides, such as cyclic di-GMP and cyclic di-AMP, which function as critical second messengers in various cellular processes. At the heart of their mechanism lies the ability of DNC inhibitors to selectively target di-nucleotide cyclases, disrupting their enzymatic activity and thus altering the delicate balance of cyclic di-nucleotides within the cellular milieu. This disruption can lead to profound downstream effects on signal transduction pathways, gene expression, and cellular behaviors. The intricacy of these interactions underscores the nuanced roles of DNC inhibitors in cellular communication and adaptation.
Structurally diverse, DNC inhibitors engage with di-nucleotide cyclases through an array of binding interactions. These interactions can involve hydrogen bonding, hydrophobic interactions, and electrostatic forces, all of which influence the inhibitory potency and specificity of these compounds. The chemical versatility of DNC inhibitors enables researchers to explore their effects on distinct isoforms of di-nucleotide cyclases, contributing to a deeper understanding of the underlying biochemical processes. While the focus remains on the molecular intricacies, the discovery and characterization of DNC inhibitors also hold broader implications. These compounds provide valuable tools for dissecting the roles of cyclic di-nucleotides in cellular responses to environmental stimuli. By selectively inhibiting di-nucleotide cyclases, researchers can uncover the cascade of events triggered by altered cyclic di-nucleotide levels, shedding light on intricate cellular regulatory networks.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacitidine incorporates into DNA, forming covalent bonds with DNMTs, trapping them and leading to DNA hypomethylation. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine is incorporated into DNA and covalently binds to DNMTs, inhibiting their activity and promoting DNA hypomethylation. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 is a small molecule inhibitor that directly targets the catalytic site of DNMTs, preventing DNA methylation by competitive inhibition. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
Zebularine is incorporated into DNA and covalently traps DNMTs, inhibiting their activity and leading to DNA hypomethylation. | ||||||
SGI-1027 | 1020149-73-8 | sc-473875 | 10 mg | $213.00 | ||
SGI-1027 targets DNMTs by interfering with their binding to DNA, leading to decreased DNA methylation levels. | ||||||
Hydralazine-15N4 Hydrochloride | 304-20-1 (unlabeled) | sc-490605 | 1 mg | $480.00 | ||
Hydralazine is thought to inhibit DNMTs by targeting their interaction with DNA, resulting in decreased DNA methylation and gene expression changes. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat inhibits DNMT1 indirectly by targeting histone deacetylases (HDACs), leading to chromatin remodeling and altered DNA methylation patterns. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat, an HDAC inhibitor, indirectly affects DNMTs by modulating chromatin structure and DNA methylation patterns through histone acetylation changes. | ||||||